Group 1 - The article announces a deadline for joining a class action lawsuit against Kyverna Therapeutics, Inc. (KYTX) [1] - The deadline to join the class action is set for February 7, 2025 [1] - The lawsuit pertains to potential grievances related to Kyverna Therapeutics, Inc. [1]

Core Viewpoint - Kyverna Therapeutics, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact investors and their interests [1] Group 1 - The lawsuit is being pursued by the Schall Law Firm, indicating potential legal ramifications for the company [1] - Investors affected by the alleged violations are encouraged to reach out to the law firm for assistance [1]

Group 1 - The article discusses a class action lawsuit involving Kyverna Therapeutics, Inc. and highlights the opportunity for shareholders to take action [1] - The law firm Bronstein, Gewirtz and Grossman, LLC is mentioned as the contact for shareholders interested in participating in the lawsuit [1] - The focus is on the potential implications for shareholders and the legal proceedings surrounding the company [1]

Group 1 - The article discusses a pending class action lawsuit against Kyverna Therapeutics, Inc. (KYTX) for shareholders who have incurred losses [1] - Shareholders are encouraged to contact the law firm Levi & Korsinsky regarding their potential claims [1] - The focus is on the financial impact on shareholders and the legal recourse available to them [1]

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX ...

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc. ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=123047&from=4CLASS PERIOD: T ...

Core Viewpoint - The article indicates that there will be exciting changes coming soon, but specific details are not yet available [1] Summary by Categories - Company Updates - The company is currently undergoing changes and encourages stakeholders to check back later for more information [1]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Kyverna Therapeutics, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) in February 2024, alleging misleading statements and omissions in the offering documents [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals who purchased or acquired Kyverna common stock during the class period associated with the February 2024 IPO [3]. - Allegations include that the defendants issued materially false and misleading statements and failed to disclose critical information regarding the IPO strategy, terms, and disclosures in the offering documents [4]. - The complaint suggests that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal representatives [4]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 7, 2025, to participate in potential recovery [5]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [5]. - There is no cost or obligation for shareholders to participate in the lawsuit [5]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing patient reach with KYV-102 using whole blood rapid manufacturing Cash run ...